EASEE® System Pivotal Study for the United States of America

NCT07301346 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-05-01

No results posted yet for this study

Summary

The goal of this clinical trial is to demonstrate the safety and effectiveness of focal cortex stimulation with the EASEE(R) System in a large cohort of subjects with medically refractory focal epilepsy. The main questions it aims to answer are:

1. Is the percentage reduction of monthly seizure rate larger in the Intervention group than in the Control group at the end of the Blinded Phase?
2. Is the use of EASEE(R) System safe after up to 28 and up to 84 days?

Participants will be asked to:

* Complete a seizure diary for the duration of the clinical trial
* Attend study visits for 20 months of their clinical trial participation
* Undergo EASEE(R) System implant
* Not be aware if neurostimulation is delivered during the Blinded Phase (6 months)
* Receive neurostimulation for at least 12 months

Conditions

  • Drug-Resistant Focal Epilepsy

Interventions

DEVICE

Implantable minimaly invasive brain stimulator

Participants are implanted with an electrode under the skin and above the skull. The electrode is connected to an implantable pulse generator in the chest area. The system is intended for focal cortex stimulation to treat medically refractory epilepsy. The stimulation is activated (turned ON) for 18 months.

DEVICE

Implantable minimaly invasive brain stimulator

Participants are implanted with an electrode under the skin and above the skull. The electrode is connected to an implantable pulse generator in the chest area. The system is intended for focal cortex stimulation to treat medically refractory epilepsy. The stimulation is not activated (turned OFF) for 6 months, than activated (turned ON) for 12 months.

Sponsors & Collaborators

  • Precisis US, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2029-07-01
Completion
2030-07-01
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07301346 on ClinicalTrials.gov